InsidersTradesSigma
Follow the JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Market capitalisation: €14.9bn. The latest transaction was reported on 15 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: MARK D SMITH. Every trade is free.
Analysts rate JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY Buy (bullish), based on 19 analysts. Average price target: US$257.95.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1 of 1 declaration
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY is a biopharmaceutical company focused on developing medicines for serious and rare diseases. It is listed on NASDAQ under the ticker symbol JAZZ.